Teva Pharmaceutical Industries Ltd. (TEVA)

11.21
0.31 2.69
NYSE : Health Technology
Prev Close 11.52
Open 11.45
Day Low/High 11.20 / 11.56
52 Wk Low/High 6.07 / 13.76
Volume 5.17M
Avg Volume 11.66M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.71B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Morning Es Trading

Morning Es Trading

Until we see a session close below 1498.25, a near-term change in direction is unlikely.

The Real Tech Boom Is Just Beginning

Keep an eye on M&A action in biotech.

Teva Pharmaceuticals downgraded at UBS

Israeli Shares to Nab on a Tumble

Israeli Shares to Nab on a Tumble

These are quality stocks, and they'd be sure to fall on a military escalation with Iran.

A Slew of Cheery Earnings

A Slew of Cheery Earnings

Here's a quick roundup of earnings from stocks we've recommended. The news has been uniformly good.

Two Robust Defensive Plays to Consider

Two Robust Defensive Plays to Consider

In the healthcare sector, TMO and TEVA are well positioned to ride out the market's current volatility.

Don't Ignore Your Health Care

Don't Ignore Your Health Care

UnitedHealth and Cigna are compelling selections for exposure to this important sector.

Updating Some Recent Picks, Part 1

Updating Some Recent Picks, Part 1

As we near the year's halfway point, here is where I stand on STJ, MET, MS and TEVA.

For Teva, the Market Hasn't Quite Caught Up

For Teva, the Market Hasn't Quite Caught Up

The stock should climb much higher following the recent favorable court ruling.

TEVA Gets Shot of Good News

TEVA Gets Shot of Good News

TEVA's patents on Copaxone will be protected until 2015, resulting in additional billion in profits for the drug maker.

A Pair of Healthy Generic Drug Makers

A Pair of Healthy Generic Drug Makers

Secular trends appear likely to favor Mylan and Teva Pharmaceuticals.

Don't Let the 'What Ifs' Get You

Don't Let the 'What Ifs' Get You

There's no shortage of fear in the markets, but selling off quality stocks doesn't make sense right now.

Teva Pharmaceuticals numbers cut at UBS

Getting Defensive With Walgreen and Teva

Getting Defensive With Walgreen and Teva

These two beaten-down health care plays have low valuations but provide good long-term value and decent dividends.

Zynga's Earnings Disappoint

Zynga's Earnings Disappoint

Zynga reported earnings that were short of estimates in its first quarter as a publicly traded company.

Playing in Biotech -- A Primer

Playing in Biotech -- A Primer

Biotech is changing, so here's how to invest amid the industry's new gold rush.

Investing in the End of the World

Investing in the End of the World

Whether or not you believe the end is nigh, let's make as much money as possible beforehand.

Is Santa on His Way?

Is Santa on His Way?

Tuesday's move was beyond my expectations, but a rally won't likely get far.

Mylan, Teva Break Through

Mylan, Teva Break Through

These two pharmaceuticals are standouts as the sector outperforms today.

Analyst Actions -- 11/3/2011

Here are today's top research calls.

Generics Could Be Exceptional

The generic drug market looks strong over the long term and should continue to perform well in the future.

The Day Ahead: European Strength Boosting Futures

Despite Alcoa's earnings miss, the major indices are pointing toward a higher open.

Fitz Bits: Gold Still Has Punch

Fitz Bits: Gold Still Has Punch

While some are looking at gold as a bubble that has popped, the yellow metal has proven itself a strong asset class through bull and bear markets alike -- so it's an asset you want to own.

Fitz Bits: Taking a Shine to Silver

Fitz Bits: Taking a Shine to Silver

Google displays two gaps.